en
Scientific article
English

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Published inLancet, vol. 395, no. 10230, p. 1115-1125
Publication date2020
Abstract

Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial.

Keywords
  • Adult
  • Antibodies
  • Monoclonal
  • Humanized/therapeutic use
  • Arthritis
  • Psoriatic/drug therapy
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha/antagonists & inhibitors
Citation (ISO format)
DEODHAR, Atul et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. In: Lancet, 2020, vol. 395, n° 10230, p. 1115–1125. doi: 10.1016/S0140-6736(20)30265-8
Main files (1)
Article (Published version)
accessLevelRestricted
Secondary files (1)
Identifiers
ISSN of the journal0140-6736
108views
0downloads

Technical informations

Creation04/28/2021 4:00:00 PM
First validation04/28/2021 4:00:00 PM
Update time03/16/2023 1:19:10 AM
Status update03/16/2023 1:19:09 AM
Last indexation01/17/2024 2:15:37 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack